TWILIGHT: Sex-Specific Outcomes

Dr. Birgit Vogel, of the Icahn School of Medicine at Mount Sinai, New York, discusses with Dr. Ron Waksman a study examining sex differences in the TWILIGHT trial, which compared patients at high risk of bleeding or ischemic events who received ticagrelor alone vs. those who received ticagrelor plus aspirin after both groups received 3 months of dual antiplatelet therapy post-percutaneous coronary intervention. The study, which was presented as a late-breaking trial at ACC.21 Virtual, found that women had a higher bleeding risk than men, but men and women had similar risk of ischemic events. The higher bleeding risk in women was mostly attributable to baseline differences.